Medical electrospinning solutions provider VIVOLTA has entered into a long-term partnership with Fibrothelium to manufacture electrospun components for use in Fibrothelium’s SimplySilk® membrane, according to an August 7, 2025, VIVOLTA press release. As the exclusive contract manufacturer of SimplySilk® membrane electrospun components, VIVOLTA will leverage its fully automated MediSpin™ technology to produce the components at commercial scale while ensuring consistent quality and regulatory compliance.
The SimplySilk® membrane, which is a resorbable barrier membrane intended to support guided bone regeneration (GBR) in dental implant procedures, periodontal procedures, and cranio-maxillofacial surgery, was developed with Fibrothelium’s proprietary silk fibroin technology. Featuring a unique multi-layer design, two porous fleece-like outer layers that promote rapid soft tissue integration, and an optional compact silk fibroin film core that slows biodegradation and enhances mechanical stability, the SimplySilk membrane ensures prolonged barrier function when clinically indicated.
Many conventional GBR membranes are derived from animal collagen. However, the SimplySilk® membrane is entirely free of animal tissue. This eliminates the risk of pathogen transmission and supports extended degradation times. Made from Fibrothelium’s biocompatible PureSilk® material, the SimplySilk membrane naturally resorbs over time, promoting safe, predictable healing of bone defects and obviating the need for removal surgery.
The press release notes that the global demand for regenerative dental solutions is rising, with the GBR membrane market estimated at roughly $520 million in 2024 and forecasted to nearly double to $950 million by 2033. This growth is largely driven by the need for advanced biomaterial membranes in implantology, and research indicates that more than 50% of dental implant patients require some form of bone grafting or GBR. With the dramatic increase in implant procedures being performed globally, the SimplySilk membrane offers clinicians a high-performance solution that provides reliable regeneration of bone tissue while minimizing complications. Currently, the SimplySilk membrane is only commercially available in Europe; however, Fibrothelium is preparing for FDA submission, with US market approval targeted for 2027.
“This partnership with Fibrothelium underscores VIVOLTA’s ability to support innovators from concept through commercialization,” says Denis Leissing, CEO of VIVOLTA. “We are excited to apply our electrospinning expertise and MediSpin™ manufacturing platform to scale up SimplySilk® membrane production. By combining Fibrothelium’s groundbreaking silk biomaterial with our unique high-volume electrospinning capabilities, we will help bring this advanced GBR membrane to dental patients worldwide. Our team is proud to enable a new animal-tissue-free solution that can improve healing and outcomes in regenerative procedures.”
“Partnering with VIVOLTA marks a key milestone in scaling the production and the global availability of our SimplySilk® membrane,” says Hans Leemhuis, CEO of Fibrothelium. “VIVOLTA’s proven know-how in electrospun medical products and its state-of-the-art MediSpin™ system give us great confidence in the quality, reproducibility and scalability of our product as we ramp up production. We look forward to delivering our SimplySilk® membrane to clinicians worldwide as a safe, effective new animal-tissue-free option for regenerative procedures that supports optimal tissue regeneration and patient care.”
